ReP USP - Resultado da busca

Filtros : "MIELOMA MÚLTIPLO" "2017" Limpar

Filtros

Artigo de periodico
Variability of high-dose melphalan exposure on oral mucositis in patients undergoing prophylactic low-level laser therapy (2017)
Rodrigues, Gustavo Henrique; Jaguar, Graziella Chagas; Alves, Fábio de Abreu; Guollo, André; Camandoni, Vanessa Oliveira; Damascena, Aline Santos; Lima, Vladmir Claudio Cordeiro
Source: Lasers in Medical Science. Unidade: FO
Subjects: MIELOMA MÚLTIPLO, LASER NÃO CIRÚRGICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RODRIGUES, Gustavo Henrique et al. Variability of high-dose melphalan exposure on oral mucositis in patients undergoing prophylactic low-level laser therapy. Lasers in Medical Science, v. 32, n. 5, p. 1089–1095, 2017Tradução . . Disponível em: https://doi.org/10.1007/s10103-017-2211-0. Acesso em: 11 out. 2024.
APA
Rodrigues, G. H., Jaguar, G. C., Alves, F. de A., Guollo, A., Camandoni, V. O., Damascena, A. S., & Lima, V. C. C. (2017). Variability of high-dose melphalan exposure on oral mucositis in patients undergoing prophylactic low-level laser therapy. Lasers in Medical Science, 32( 5), 1089–1095. doi:10.1007/s10103-017-2211-0
NLM
Rodrigues GH, Jaguar GC, Alves F de A, Guollo A, Camandoni VO, Damascena AS, Lima VCC. Variability of high-dose melphalan exposure on oral mucositis in patients undergoing prophylactic low-level laser therapy [Internet]. Lasers in Medical Science. 2017 ; 32( 5): 1089–1095.[citado 2024 out. 11 ] Available from: https://doi.org/10.1007/s10103-017-2211-0
Vancouver
Rodrigues GH, Jaguar GC, Alves F de A, Guollo A, Camandoni VO, Damascena AS, Lima VCC. Variability of high-dose melphalan exposure on oral mucositis in patients undergoing prophylactic low-level laser therapy [Internet]. Lasers in Medical Science. 2017 ; 32( 5): 1089–1095.[citado 2024 out. 11 ] Available from: https://doi.org/10.1007/s10103-017-2211-0
Artigo de periodico
Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: an overview of systematic reviews with meta-analyses (2017)
Aguiar, Patrícia Melo ; Lima, Tácio de Mendonça; Colleoni, Gisele Wally Braga; Storpirtis, Silvia
Source: Critical Reviews in Oncology Hematology. Unidade: FCF
Subjects: MIELOMA MÚLTIPLO, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
AGUIAR, Patrícia Melo et al. Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: an overview of systematic reviews with meta-analyses. Critical Reviews in Oncology Hematology, v. 113, p. 195-212, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.critrevonc.2017.03.014. Acesso em: 11 out. 2024.
APA
Aguiar, P. M., Lima, T. de M., Colleoni, G. W. B., & Storpirtis, S. (2017). Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: an overview of systematic reviews with meta-analyses. Critical Reviews in Oncology Hematology, 113, 195-212. doi:10.1016/j.critrevonc.2017.03.014
NLM
Aguiar PM, Lima T de M, Colleoni GWB, Storpirtis S. Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: an overview of systematic reviews with meta-analyses [Internet]. Critical Reviews in Oncology Hematology. 2017 ; 113 195-212.[citado 2024 out. 11 ] Available from: https://doi.org/10.1016/j.critrevonc.2017.03.014
Vancouver
Aguiar PM, Lima T de M, Colleoni GWB, Storpirtis S. Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: an overview of systematic reviews with meta-analyses [Internet]. Critical Reviews in Oncology Hematology. 2017 ; 113 195-212.[citado 2024 out. 11 ] Available from: https://doi.org/10.1016/j.critrevonc.2017.03.014

Digital Library of Intellectual Production of Universidade de São Paulo 2012 - 2024